Observing the effects of foam sclerotherapy on kidney and liver cysts

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to evaluate the impact of foam sclerotherapy on large kidney and liver cysts in patients with autosomal dominant polycystic kidney disease (ADPKD) and autosomal dominant polycystic liver disease (ADPLD). It will assess changes in cyst volumes and quality of life outcomes over a follow-up period of up to 12 months. The study will utilize a patient-reported outcome tool specifically designed for polycystic liver disease to gather relevant data. By focusing on patients with significant cyst burden, the study seeks to provide insights into the effectiveness of this treatment approach.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age ≥18 years
* Clinical diagnosis of ADPKD or ADPLD
* 1-3 large, non-exophytic liver or kidney cyst
* Compressive symptoms from dominant cyst

Exclusion Criteria:

* Age \<18 years
* Absence of ADPKD or ADPLD
* Largest cyst \<4cm in all 3 dimensions or largest cyst volume \<400cc
* \>3 large, non-exophytic liver or kidney cyst(s) ≥4cm in all 3 dimensions (cyst volume ≥400cc)
* Unwilling to comply with study follow-up protocol to 12 ± 1months post-FS
* Lacking capacity to provide informed consent to FS of liver or kidney cysts
* Pregnancy

Where it's running

• Mayo Clinic
  Rochester, Minnesota, United States Recruiting

Study contacts

• Principal investigator: Marie Hogan, MD, PhD — Mayo Clinic
• Study coordinator: Cassie Howe, CRC
• Email: howe.cassie@mayo.edu
• Phone: 507-266-1230

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Database analysis of patients with Autosomal Dominant Polycystic Kidney Disease

  This study is trying to gather and track health information from people with Autosomal Dominant Polycystic Kidney Disease to see how different treatments affect their kidney function and cyst growth over time.

  Recruiting IRCCS Azienda Ospedaliero-Universitaria di Bologna · Bologna · NCT06759142

• Using a medication to slow kidney growth in patients with a genetic kidney disease

  This study is testing if a new medication can help slow down kidney growth in overweight or obese adults with a genetic kidney disease called ADPKD.

  Recruiting Phase 2 University of Colorado, Denver · Aurora, Colorado · NCT06582875

• Using RNA sequencing to diagnose rare genetic diseases

  This study is testing if a new RNA sequencing method can help find the genetic causes of rare diseases in people who haven't been diagnosed after other tests.

  Recruiting Mario Negri Institute for Pharmacological Research · Ranica, BG · NCT05996731

• Using a GnRH Agonist to Treat Severe Polycystic Liver Disease in Women

  This study is testing if a medication called leuprorelin can help reduce liver size in women with severe polycystic liver disease who are still experiencing growth despite other treatments.

  Recruiting Phase 2 University Medical Center Groningen · Nijmegen, Gelderland and 1 other locations · NCT05478083

• Managing Depressive Symptoms in ADPKD: testing Digital Neurotherapy and Capacity Coaching

  This study tests whether Digital Neurotherapy or Capacity Coaching can help people with ADPKD who have depression and self-reported pain, compared to education alone.

  Recruiting Mayo Clinic · Rochester, Minnesota · NCT07745920

• AZD1613 safety and how the body handles it in adults with ADPKD

  We will test whether AZD1613 given under the skin or into a vein is safe and how the body processes it in adults with ADPKD who have eGFR between 45 and 90 mL/min/1.73m2.

  Recruiting at 10 sites Phase 1 AstraZeneca · Birmingham, Alabama and 14 other locations · NCT07228364

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.